A Consultant’s Approach to Improving Patient Experience

 
A 2020 American Heart Association survey found that patients defined value as communication and trust in healthcare providers and not simply cost and services. Building trust and improving patient experience is something that healthcare organizations learned first-hand over the past three years through an unprecedented health crisis.

Stellar customer service is not a choice in healthcare, and in this competitive market a lack of committed service excellence could cost. If improving patient experience and service prove elusive for a healthcare organization, they may turn to the experts for sound strategies.

I Don’t Care’s Kevin Stevenson spoke with Amanda Brummitt, founder of the Brummitt Group. The Brummitt Group specializes in strategies for executing stellar patient experiences, something Brummitt believes is more than a sound business practice; it just makes plain sense.

“Being good to our patients is vital,” Brummitt said. “I think it’s easier keeping existing patients happy than it is to acquire new patients.”

Stevenson and Brummitt discuss…

● Creating the expectation for great customer service from the top down in an
organization

● Generating a new organizational culture to redefine the patient experience

● How the right script can transform customer service and patient satisfaction

“The script is a jumping-off point,” Brummitt said. “Let’s say you’re new to a call center or you’re new to a front-desk position in a hospital. Let’s start with a script, and once you have your own magic style, tweak the script. And if your scores look good and patients aren’t complaining, you can say whatever you want to say. But I’ve yet to find an alternative better than scripting, and we use it in our own business.”

Amanda Brummitt is the CEO of The Brummitt Group, a boutique healthcare consulting company focused on operations, strategic development, and patient experience for hospitals, ambulatory surgery centers, physician practices, and other healthcare areas. Brummitt received her master’s in Health Administration from the USC Sol Price School of Public Policy. Brummitt, a volunteer advocate, received the volunteer of the year from the ACHE of North Texas in 2022.

Follow us on social media for the latest updates in B2B!

Image

Latest

cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More
organoids
Growing the Future of Cancer Research: Inside the Promise of Organoids
April 19, 2025

In an era where precision and predictability define the future of oncology, organoid technology is emerging as a transformative tool in drug discovery. These miniature, lab-grown 3D tissues mirror real human biology more closely than traditional 2D models or even animal systems, offering researchers the potential to predict patient-specific drug responses. As organoids become more…

Read More